C A Uyl-de Groot
Overview
Explore the profile of C A Uyl-de Groot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma
de Groot S, Redekop W, Versteegh M, Sleijfer S, Oosterwijk E, Kiemeney L, et al.
Qual Life Res
. 2017 Sep;
27(1):115-124.
PMID: 28917029
Purpose: Based on improvements of progression-free survival (PFS), new agents for metastatic renal cell carcinoma (mRCC) have been approved. It is assumed that one of the benefits is a delay...
12.
Goorden M, Willemsen E, Bouwmans-Frijters C, Busschbach J, Noomx M, van der Feltz-Cornelis C, et al.
BMC Psychiatry
. 2017 Sep;
17(1):317.
PMID: 28859629
Background: Current guidelines recommend referral to highly specialized care for patients with severe personality disorders. However, criteria for allocation to highly specialized care are not clearly defined. The aim of...
13.
de Groot S, Blommestein H, Redekop W, Sleijfer S, Kiemeney L, Oosterwijk E, et al.
PLoS One
. 2017 May;
12(5):e0177364.
PMID: 28531203
Introduction: Randomised controlled trials have shown that targeted therapies like sunitinib are effective in metastatic renal cell carcinoma (mRCC). Little is known about the current use of these therapies, and...
14.
Franken M, van Rooijen E, May A, Koffijberg H, van Tinteren H, Mol L, et al.
Eur J Cancer
. 2017 Feb;
75:204-212.
PMID: 28237866
Aim: Capecitabine and bevacizumab (CAP-B) maintenance therapy has shown to be more effective compared with observation in metastatic colorectal cancer patients achieving stable disease or better after six cycles of...
15.
de Groot S, Sleijfer S, Redekop W, Oosterwijk E, Haanen J, Kiemeney L, et al.
BMC Cancer
. 2016 Jun;
16:364.
PMID: 27286871
Background: For patients with metastatic renal cell carcinoma (mRCC), targeted therapies have entered the market since 2006. The aims of this study were to evaluate the uptake and use of...
16.
Zaim R, Tran L, Groen H, Uyl-de Groot C
Value Health
. 2016 May;
17(7):A641.
PMID: 27202295
No abstract available.
17.
Van der Linden N, Smit E, Uyl-de Groot C
Value Health
. 2016 May;
17(7):A622-3.
PMID: 27202194
No abstract available.
18.
Leeneman B, Franken M, Blommestein H, van Gils C, van der Meijde E, Wouters M, et al.
Value Health
. 2016 May;
17(7):A618-9.
PMID: 27202168
No abstract available.
19.
Bongers M, De Ruysscher D, Oberije C, Lambin P, Uyl-de Groot C, Coupe V
Value Health
. 2016 May;
17(7):A561.
PMID: 27201853
No abstract available.
20.
Leunis A, Redekop W, Lowenberg B, Uyl-de Groot C
Value Health
. 2016 May;
17(7):A551-2.
PMID: 27201799
No abstract available.